Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
Monoclonal antibodies that target T cells offer an alternative to conventional immunosuppressive drugs in the management of autoimmune disease. "Humanisation" of such monoclonal antibodies makes their clinical use less likely to be prone to the risk of cross-species sensitisation than trea...
Main Authors: | Lockwood, C, Thiru, S, Isaacs, J, Hale, G, Waldmann, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1993
|
Similar Items
-
MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
by: Isaacs, J, et al.
Published: (1993) -
HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
by: Lockwood, C, et al.
Published: (1993) -
Monoclonal-antibody therapy in systemic vasculitis.
by: Mathieson, P, et al.
Published: (1990) -
MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
by: Mathieson, P, et al.
Published: (1990) -
HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
by: Lockwood, C, et al.
Published: (1995)